PL1713458T3 - Sposób poprawienia dostępności biologicznej ospemifenu - Google Patents

Sposób poprawienia dostępności biologicznej ospemifenu

Info

Publication number
PL1713458T3
PL1713458T3 PL05701734T PL05701734T PL1713458T3 PL 1713458 T3 PL1713458 T3 PL 1713458T3 PL 05701734 T PL05701734 T PL 05701734T PL 05701734 T PL05701734 T PL 05701734T PL 1713458 T3 PL1713458 T3 PL 1713458T3
Authority
PL
Poland
Prior art keywords
bioavailability
enhancing
ospemifene
compound
stereoisomer
Prior art date
Application number
PL05701734T
Other languages
English (en)
Polish (pl)
Inventor
Markku Anttila
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1713458(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of PL1713458T3 publication Critical patent/PL1713458T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL05701734T 2004-02-13 2005-01-14 Sposób poprawienia dostępności biologicznej ospemifenu PL1713458T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene
EP05701734A EP1713458B1 (en) 2004-02-13 2005-01-14 Method for enhancing the bioavailability of ospemifene
PCT/FI2005/000018 WO2005077350A1 (en) 2004-02-13 2005-01-14 Method for enhancing the bioavailability of ospemifene

Publications (1)

Publication Number Publication Date
PL1713458T3 true PL1713458T3 (pl) 2008-08-29

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05701734T PL1713458T3 (pl) 2004-02-13 2005-01-14 Sposób poprawienia dostępności biologicznej ospemifenu

Country Status (23)

Country Link
US (5) US8236861B2 (instruction)
EP (1) EP1713458B1 (instruction)
JP (2) JP5577011B2 (instruction)
CN (1) CN1925847A (instruction)
AT (1) ATE387910T1 (instruction)
AU (1) AU2005211958B2 (instruction)
BE (1) BE2015C033I2 (instruction)
BR (1) BRPI0507661A (instruction)
CA (1) CA2556089C (instruction)
CY (2) CY1111014T1 (instruction)
DE (1) DE602005005165T2 (instruction)
DK (1) DK1713458T5 (instruction)
ES (1) ES2302177T3 (instruction)
FR (1) FR15C0041I2 (instruction)
HU (1) HUS1500030I1 (instruction)
LT (1) LTC1713458I2 (instruction)
LU (1) LU92736I2 (instruction)
MX (1) MXPA06009274A (instruction)
NO (2) NO337656B1 (instruction)
PL (1) PL1713458T3 (instruction)
PT (1) PT1713458E (instruction)
RU (1) RU2385716C2 (instruction)
WO (1) WO2005077350A1 (instruction)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
SI2275098T1 (sl) 2004-05-04 2012-12-31 Hormos Medical Ltd. Nove oralne formulacije ospemifena
RU2008122993A (ru) * 2005-11-09 2009-12-20 Хормос Медикал Лтд. (Fi) Препаративные формы фиспемифена
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
EA201500845A1 (ru) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. Агенты, связывающиеся с ядерными рецепторами
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
SI2121553T1 (sl) * 2007-02-14 2012-11-30 Hormos Medical Ltd Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-(对-((z-4-氯-1,2-二苯基-1-丁烯基)苯氧基)乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
CN120549929A (zh) 2018-05-11 2025-08-29 泽农医药公司 用于增强生物利用度和电压门控钾离子通道开放暴露的方法
TWI886158B (zh) 2019-10-10 2025-06-11 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
CR20220250A (es) 2019-11-08 2022-08-19 Xenon Pharmaceuticals Inc Métodos para el tratamiento de trastornos depresivos
WO2022173855A1 (en) 2021-02-09 2022-08-18 Xenon Pharmaceuticals Inc. Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
WO2000008001A1 (en) * 1998-08-07 2000-02-17 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
US6219674B1 (en) 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
CA2438816A1 (en) 2001-02-22 2002-09-06 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
KR100991157B1 (ko) 2002-06-06 2010-11-02 호르모스 메디칼 리미티드 여성의 위축 억제 또는 위축관련 증상 치료 또는 예방 방법
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20050187302A1 (en) 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8758821B2 (en) 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Also Published As

Publication number Publication date
RU2006132719A (ru) 2008-03-20
LU92736I2 (fr) 2015-08-10
US20120270952A1 (en) 2012-10-25
NO339190B1 (no) 2016-11-14
CN1925847A (zh) 2007-03-07
JP2014141533A (ja) 2014-08-07
JP6023119B2 (ja) 2016-11-09
US8470890B2 (en) 2013-06-25
US20130324614A1 (en) 2013-12-05
US20160101065A1 (en) 2016-04-14
NO20063960L (no) 2006-11-03
EP1713458A1 (en) 2006-10-25
NO20151603L (no) 2006-11-03
AU2005211958A1 (en) 2005-08-25
EP1713458B1 (en) 2008-03-05
ATE387910T1 (de) 2008-03-15
US9855224B2 (en) 2018-01-02
FR15C0041I2 (fr) 2015-11-13
CY2015027I2 (el) 2016-04-13
US8772353B2 (en) 2014-07-08
US8236861B2 (en) 2012-08-07
CA2556089A1 (en) 2005-08-25
DE602005005165D1 (de) 2008-04-17
DK1713458T3 (da) 2008-07-07
RU2385716C2 (ru) 2010-04-10
US20140303259A1 (en) 2014-10-09
US9241915B2 (en) 2016-01-26
US20050182143A1 (en) 2005-08-18
DK1713458T5 (da) 2008-09-29
NO337656B1 (no) 2016-05-23
CA2556089C (en) 2013-04-02
HUS1500030I1 (hu) 2015-08-28
LTPA2015023I1 (lt) 2015-08-25
FR15C0041I1 (instruction) 2015-07-17
BE2015C033I2 (instruction) 2024-08-08
CY1111014T1 (el) 2015-06-11
JP2007522190A (ja) 2007-08-09
LTC1713458I2 (lt) 2017-06-26
AU2005211958B2 (en) 2010-11-25
DE602005005165T2 (de) 2009-04-30
MXPA06009274A (es) 2007-04-16
PT1713458E (pt) 2008-05-07
ES2302177T3 (es) 2008-07-01
WO2005077350A1 (en) 2005-08-25
BRPI0507661A (pt) 2007-07-17
CY2015027I1 (el) 2016-04-13
JP5577011B2 (ja) 2014-08-20

Similar Documents

Publication Publication Date Title
LTC1713458I2 (lt) Ospemifeno bioaktyvumo padidinimo būdas
SI1718288T1 (sl) Trdna formulacija ospemifena
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
TW200728307A (en) Novel spirochromanone derivatives
CA2665931C (en) Hydrobenzamide derivatives as inhibitors of hsp90
UA105229C2 (uk) Фармацевтичний склад
EP2404912A3 (en) Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
DK1678162T3 (da) P-glycoprotein-inhibitor, fremgangsmåde til fremstilling heraf og farmaceutisk sammensætning omfattende denne
IL181155A0 (en) 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase i?á
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
NO20082181L (no) Formuleringer av Fispemifen
EA200801619A1 (ru) Способ улучшения фармакокинетики ингибиторов интегразы вич (варианты), набор и фармацевтическая композиция (варианты)
WO2007133481A3 (en) Method for increasing the bioavailability of benzhydryl piperazine containing compounds
WO2009011901A3 (en) Methods for promoting wakefulness
WO2008099781A1 (ja) アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤
IL164528A (en) Method for inhibition of atrophy or for treatment or prevention of atrophy related symptoms in women
WO2007133476A3 (en) Competitive substrate inhibition to increase drug bioavailability
RU2004116385A (ru) Средство для коррекции уролого-андрологической патологии
MX2010000624A (es) Metodo para promover la vigilia.
BRPI0510465A (pt) formulação de droga oral semi-sólida ou lìquida
MXPA05008884A (es) Promotor para el crecimiento de vasos sanguineos.
DE602005016711D1 (de) Isoxazolsäure-derivat zur linderung neuropathischer schmerzen